Article Text

Download PDFPDF

#490 National cancer research institute (NCRI) survey of hormone replacement therapyprescribing in gynaecological and breast cancer survivors and in women who have had risk-reducing oophorectomy in the United Kingdom
  1. Gabriella Yongue1,
  2. Rowan Miller1,
  3. Areen Abu Remilah2 and
  4. Shibani Nicum3,4
  1. 1University College London Hospital, London, UK
  2. 2Shaare Zedek Medical Center, Jerusalem, Israel
  3. 3University College London Cancer Institute, London, UK
  4. 4National Cancer Research Institute, London, UK


Introduction/Background There is limited prospective data of the safety of hormone replacement therapy (HRT) following cancer treatment. Many clinicians are reluctant to prescribe HRT due to the fear of promoting cancer recurrence and this has led to many women struggling with menopausal symptoms, significantly impacting quality of life. This was highlighted in a recent UK patient survey, led by the charity, Target Ovarian Cancer, that identified a huge need in women with gynaecological cancer: 67% of patients wanted help with menopausal symptoms and for 62% this was not discussed at any timepoint during their cancer treatment.

Methodology The NCRI electronically distributed a multiple choice questionnaire to clinicians including general practitioners (GPs), gynaecologists, surgeons, oncologists and nurse practitioners. The survey was open between: 12/4/23 and 12/05/23. The survey addressed clinicians current HRT prescribing practice in breast, ovarian and endometrial cancer survivors and also in those who had undergone risk-reducing oophorectomy (RRO) due to a hereditary risk of cancer.

Results A total of 141 health professionals completed the survey: 13(9.2%) general gynaecologists, 51(36.1%) GPs, 5(3.5%) menopause specialists, 20(14.1%) gynaecological oncologists, 35(24.8%) medical/clinical oncologists, 15(10.6%) nurse practitioners and 2(1.4%) oncoplastic breast surgeons. Overall, 130(92.9%) respondents felt that there was not sufficient information and awareness with regards to prescribing HRT following a gynaecological malignancy. Only a minority of clinicians would feel confident in prescribing HRT for cancer survivors: 12.8% in breast cancer, 25.5% in ovarian, 27.0% in endometrial and 29.8% RRO.

Conclusion This survey demonstrated that additional support with decision making is urgently required for clinicians prescribing HRT to gynaecological and breast cancer survivors and in those who undergo risk reducing surgery. Further research to clarify the impact of HRT on gynaecological cancer recurrence and identifying those most at risk is an important ongoing area of research.

Disclosures Nil

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.